On page S73 of the article listed above, the sentence “U-300 glargine and U-200 degludec are three and two times as concentrated as their U-100 formulations, have longer durations of action, and allow higher doses of basal insulin administration per volume used” incorrectly stated that U-200 degludec has a longer duration of action than U-100 degludec. The duration of action for U-100 degludec and U-200 degludec is the same. The text has been changed to reflect this: “U-300 glargine and U-200 degludec are three and two times as concentrated as their U-100 formulations and allow higher doses of basal insulin administration per volume used. U-300 glargine has a longer duration of action than U-100 glargine.”

The online version reflects this change.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.